Atherosclerotic background of cirrhosis in patients with sickle cell diseases;Antecedentes ateroscleróticos de cirrosis en pacientes con anemia drepanocítica

Prensa Medica Argentina

Volumn 100, Issue 2, 2014, Pages 127-133

  Helvaci, Mehmet Rami ^a   Sevinc, Alper ^b   Camci, Celaletdin ^b   Keskin, Ali ^c  

^a Facultad de Medicina Universidad Kemal Mustafa   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c Facultad de Medicina Universidad de Pamukkale   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905003471     PISSN: 0032745X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lan-cet 2005;365:1415-1428.
2. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Defini-tion of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circula-tion 2004;109:433-438.
3. Helvaci MR, Kaya H, Gundogdu M. Association of increased triglyceride levels in metabolic syndrome with coronary artery disease. Pak J Med Sci 2010;26:667-672.
4. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of phy-sical health. Intern Med 2008;47:697-703.
5. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! Intern Med 2006;45:671-674.
6. Helvaci MR, Kaya H, Sevinc A, Ca-mci C. Body weight and white coat hypertension. Pak J Med Sci 2009;25:916-921.
7. Helvaci MR, Aydin LY, Aydin Y. Chronic obstructive pulmonary di-sease maybe one of the terminal end points of metabolic syndrome. Pak J Med Sci 2012;28:376-379.
8. Anderson RN, Smith BL. Deaths: leading causes for 2001. Natl Vital Stat Rep 2003;52:1-85.
9. Helvaci MR, Kaya H. Effect of sickle cell diseases on height and weight. Pak J Med Sci 2011;27:361-364.
10. Global strategy for the diagnosis, ma-nagement and prevention of chronic obstructive pulmonary disease 2010. Global initiative for chronic obstruc-tive lung disease (GOLD).
11. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Do-ppler echocardiography in the he-modynamic assessment of pulmo-nary hypertension. Am J Respir Crit Care Med 2009;179:615-621.
12. Schamroth L. Personal experience. S Afr Med J 1976;50:297-300.
13. Vandemergel X, Renneboog B. Pre-valence, aetiologies and significance of clubbing in a department of ge-neral internal medicine. Eur J Intern Med 2008;19:325-329.
14. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, et al. Hepatitis C infection and clearance: impact on atherosclero-sis and cardiometabolic risk factors. Gut 2010;59:1135-1140.
15. Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, et al. Immune activation resulting from NKG2D/ligand interaction pro-motes atherosclerosis. Circulation 2011;124:2933-2943.
16. Bonora E, Targher G. Increased risk of cardiovascular disease and chron-ic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol 2012;9:372-381.
17. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important car-diovascular risk factor? Eur Heart J 2012;33:1190-1200.
18. Pacifico L, Nobili V, Anania C, Ver-decchia P, Chiesa C. Pediatric non-alcoholic fatty liver disease, meta-bolic syndrome and cardiovascular risk. World J Gastroenterol 2011;17:3082-3091.
19. Maurantonio M, Ballestri S, Odoar-di MR, Lonardo A, Loria P. Treat-ment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res 2011;42:337-353.
20. Mawatari S, Uto H, Tsubouchi H. Chronic liver disease and arterio-sclerosis. Nihon Rinsho 2011;69:153-157.
21. Bugianesi E, Moscatiello S, Ciarav-ella MF, Marchesini G. Insulin re-sistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-1951.
22. Helvaci MR, Aydogan F, Sevinc A, Camci C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. Pren Med Argent 2014;100:49-56. Spanish
23. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Wei-ner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-89.
24. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992;120:360-366.